Louis, and colleagues randomly assigned 206 African-American children (ages 6 to 17 years) with mild asthma managed by 12 primary care providers (PCPs) to either symptom-based adjustment (SBA), which involved as-needed beclomethasone
80 [micro]g with rescue short-acting ?-agonist, or provider-based guideline-directed adjustment (PBA), which involved maintenance beclomethasone
80 [micro]g/d (6 to 11 years old), 160 [micro]g/d (12 to 17 years old), with subsequent guideline-based dose adjustment by PCPs.
Each participant in one group was advised to take a dose from an inhaler containing the steroid beclomethasone
as needed when symptoms arose, along with the rescue bronchodilator albuterol.
First-line drugs are topical glucocorticoids (beclomethasone
, mometasone, budesonide, fluticasone) for intranasal use, showing a high therapeutic efficacy, especially in patients with burdened or resistant AR (12).
Contract notice: active substance combination formoterol and beclomethasone
A study showed that 7 of 10 children on maintenance doses of beclomethasone
dipropionate had growth impairment after 6 months of therapy.
(NYSE and TASE: TEVA) has made the QVAR RediHaler (beclomethasone
dipropionate HFA) Inhalation Aerosol commercially available by prescription to patients in both 40 mcg and 80 mcg strengths in the US, the company said.
M2 EQUITYBITES-February 20, 2018-Teva Pharmaceutical in US launch of QVAR RediHaler (beclomethasone
dipropionate HFA) Inhalation Aerosol
The participating children used beclomethasone
, budesonide, ciclesonide, flunisolide, fluticasone, or mometasone, delivered by any type of inhalation device, and were followed for 3 months to 6 years.
Its active ingredient is beclomethasone
, which in this product is available as beclomethasone
According to Teva, QNASL (beclomethasone
dipropionate), for adults and children age 12 and older, began shipping to pharmacies in April and was the first marketed nonaqueous nasal aerosol in a product category that generates annual sales of $2.5 billion.
Soligenix, Inc., Princeton, NJ, announced the National Cancer Institute (NCI) has awarded the company a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 2 clinical trial designed to evaluate orBec (oral beclomethasone
17, 21-dipropionate) as a treatment for the gastrointestinal (GI) manifestation of chronic Graft-versus-Host disease (GvHD).
The daily ICS regimen consisted of one 40-mcg puff of beclomethasone
twice daily; combined treatment consisted of one 40-mcg puff of beclomethasone
with each albuterol puff used for symptom relief.